

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) (Stock Code 股份代號: 1498)

NOTIFICATION LETTER 通知信函

30 April 2024

Dear registered shareholder(s),

Purapharm Corporation Limited (the "Company")

- Notice of Publication of 2023 Annual Report and Circular together with Proxy Form (the "Current Corporate Communications")

The Current Corporate Communications of the Company has been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong Limited ("HKEX") at www.hkexnews.hk and the Company's website at www.purapharm.com. If you have any difficulty in receiving or gaining access to the Current Corporate Communications posted on the Company's website for any reason, please send your request (specifying your name, address and request) by email at purapharm.ecom@computershare.com.hk or by notice in writing to the Company's Hong Kong share registrar (the "Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong. The Company will promptly upon receipt of your request send the Current Corporate Communications to you in printed form free of charge.

Arrangement of Electronic Dissemination of Corporate Communications and Solicitation of Electronic Contact Details

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") relating to the expansion of paperless listing regime and electronic dissemination of corporate communications, which came into effect on 31 December 2023, the Company is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"). Corporate Communications mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.purapharm.com and the HKEXnews website at www.hkexnews.hk in place of printed copies. To ensure timely receipt of the latest Corporate Communications, the Company recommends you provide your email address by scanning your personalized QR code printed on the reply form (the "Reply Form") on the reverse side. Alternatively, you may sign and return the Reply Form to the Share Registrar.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, you will (i) be unable to receive any notifications regarding the publication of Corporate Communications by email; (ii) need to proactively check the Company's website and the HKEXnews website to keep up with the publication of Corporate Communications; and (iii) the Company will send the Actionable Corporate Communications' in printed form in the future.

If you want to receive the Corporate Communications in printed form, please complete the Reply Form on the reverse side and send it to the Share Registrar or send an email to <u>purapharm.ecom@computershare.com.hk</u> specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter. Should you have any queries relating to this letter, please contact the Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

By Order of the Board of Director PuraPharm Corporation Limited Chan Yu Ling, Abraham Chairman and executive Director

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

培力農本方有限公司(「公司」)

-2023 年報及通函連同代表委任表格(「本次公司通訊」)的刊發通知

本次公司通訊文件備有中、英文版本,並已上載於香港聯合交易所有限公司(「**香港交易所**」)網站(<u>www.hkexnews.hk</u>)及公司網站(<u>www.purapharm.com</u>) 歡迎瀏覽。 閣下若因任何理由以致在收取或接收載於公司網站上的本次公司通訊文件出現困難, 閣下可將要求(註明 閣下的姓名、地址及 要求)以電郵方式發送至 <u>purapharm.ecom@computershare.com.hk</u> 或以書面方式郵寄至公司香港股份過戶登記處(「**股份過戶處**」)香港中央證 券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。公司將於收悉 閣下通知後,盡快向 閣下免費發送有關本次公司通訊 文件的印刷本。

以電子方式發布公司通訊之安排及徵集電子聯絡資料

根據自 2023 年 12 月 31 日起生效的擴大無紙化制度及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則(「**上市規則**」)第 2.07條,公司謹此通知 閣下,公司已採用以電子方式發布公司通訊(「**公司通訊**」)之安排,該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b)中期報告及其中期報告摘要(如適用); (c)會議通知; (d)上市文件; (e)通函和 (f)委任表格。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 www.purapharm.com 和披露易網站 www.hkexnews.hk 上提供,以代替印刷本。為確保及時收到最新的公司通訊,公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。 或者, 閣下也可以簽署回條並交回股份過戶處。

如果公司沒有收到 閣下的有效電子郵件地址,直至股份過戶處收到 閣下有效的電子郵件地址前, 閣下將(i)無法通過電子郵件方式收到任何有關發佈公司通訊的通知;(ii)需要主動查看公司網站和披露易網站以留意公司通訊的發佈;及(iii)本公司未来將以印刷本形式發送可供採取行動的公司通訊(###)。

若 閣下希望收取未來公司通訊之印刷版,請填妥回條本函背頁之回條並交回股份過戶處,或發送電子郵件至 purapharm.ecom@computershare.com.hk,並註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。 請注意,收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一年內有效,此後將過期。如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午 9 時正至下午 6 時正(香港時間)期間致電股份過戶處(852)2862 8688 查詢。

承董事會命 **培力農本方有限公司** *主席及執行董事* **陳宇齡**

REPLY 1	FORM	回條
---------	------	----

Computershare Hong Kong Investor Services Limited

(The "Share Registrar") 17M Floor, Hopewell Centre

183 Queen's Road East, Wanchai, Hong Kong

香港中央證券登記有限公司 (「股份過戶處」) 香港灣仔皇后大道東 183 號 合和中心 17M 樓

(Please <u>choose ONLY ONE</u> of the options below) (請<u>從以下選項中**只選擇其中一項**)</u>

Personalized QR Code 專屬二維碼

Option 1: Provide your email address for receipt of future Corporate Communications* of the Company via electronic dissemination by scanning your personalized QR code

掃描 閣下專屬二維碼提供 閣下之電子郵件地址,以接收公司通過電子方式 選項1: 發布的未來公司通訊*

> You are **NOT required** to return this Reply Form if you choose Option 1. 如選擇了選項1, 閣下無須交回本回條。

Option 2: I/we hereby provide my/our email address in writing for receipt of future Corporate Communications* of the following listed company (the				
"Company") via electronic dissemination				
選項 2: 本人/吾等現以書面提供本人/吾等之的電子郵件地址,以確保收到以下上市公司(「公司」)通過電子方式發布的未來公司通訊*				
Name of Securities holder(s) 證券持有人姓名:	urities holder(s) 證券持有人姓名: Name of the listed company 上市公司名稱:			
PURAPHARM CORPORATION LIMITED				
Email address 電郵地址: (Note 3 / 附註3)		_		
Option 3: I/we hereby request for receipt of Corporate Communications* in printed form (Please mark "✓" in the below box if applicable)				
選項3: 本人/吾等現要求收取公司通訊*印刷版 (如適用·請在以下方格內劃上「✓」號)				
receive future Corporate Communications* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction. (Note 5) 收取未來公司通訊"的印刷本·並已知悉本指示由收取指示日期起計一年內有效。(常註5)				
Signature(s): (Note 1)	Contact number:	Date:		
(RU *L #)	聯絡電話號碼:	日期:		
Notes 附註: 1. Please complete all your details clearly. If your shares are held in joint names, all of the	joint shareholders should jointly sign this Reply Form in order to be val	id.		

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- 個人資料聲明

 "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").

 本聲明中所指的「個人資料」與香港法例第 486章 《個人資料(私隱)條例》(「《私隱條例》」)中「個人資料」的涵義相同。

 Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications* and to liaise with you on other matters relating to you holdings in the Company, Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.

 圖下於本心包修所提供的自人資料無用於(包括但不限於)有關公司以電子方式發布公司通訊》及就 圖下持有的公司證券有關的其他事宜上與 圖下聯絡。圖下是自願向本公司提供個人資料。若 圖下未能提供足夠資料。本公司可能無法處理 圖下在本回條上所述的指示及/或要求。

 Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.

 公司可能任何所說的印刷证实在法例规定对给例证的条件,例如人资料技术或的人资料或其他公司或問題。並将在適當期間保留該等個人資料作核實及經濟用途。

 You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Frivacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong or by email at Privacy Officer @computershare.com.ht.

 [18] 在提供的表的表面,是可以表现的是可以表现的是更具体的一个可以表现的是更具体

Mailing Label 郵寄標籤

香港中央證券登記有限公司 Freepost No. 簡便回郵號碼:37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

閣下寄回此回條時·請將郵寄標籤剪貼於信封上 如在本港投寄· 閣下無需支付郵費或貼上郵票。